Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company now part of Johnson & Johnson, founded on Nobel Prize-winning research. The company leverages intracellular approaches to develop treatments for complex psychiatric and neurologic diseases, aiming to deliver innovative treatments to improve lives and reduce burdens on patients and caregivers.
Industries
Nr. of Employees
large (251-1000)
Intra-Cellular Therapies, Inc.
135 Route 202/206, Suite 6, Bedminster, NJ 07921
Patents
Products
FDA-approved oral small-molecule therapy for neuropsychiatric indications
A commercially available, orally administered small-molecule treatment approved by the FDA for specified neuropsychiatric indications; accompanied by formal prescribing information and boxed warnings.
Pipeline of investigational CNS compounds
A portfolio of investigational small-molecule compounds across preclinical and clinical stages evaluated for neuropsychiatric and neurologic indications.
FDA-approved oral small-molecule therapy for neuropsychiatric indications
A commercially available, orally administered small-molecule treatment approved by the FDA for specified neuropsychiatric indications; accompanied by formal prescribing information and boxed warnings.
Pipeline of investigational CNS compounds
A portfolio of investigational small-molecule compounds across preclinical and clinical stages evaluated for neuropsychiatric and neurologic indications.
Services
Telephone and email channels for medical inquiries and reporting of adverse events related to marketed therapies.
Programs and resources to support patient access to approved therapies.
Centralized information and request process for donations, sponsorships, healthcare provider education, and research funding.
Telephone and email channels for medical inquiries and reporting of adverse events related to marketed therapies.
Programs and resources to support patient access to approved therapies.
Centralized information and request process for donations, sponsorships, healthcare provider education, and research funding.
Expertise Areas
- Small-molecule CNS drug discovery
- Platform-based discovery and optimization
- Clinical development for neuropsychiatric and neurologic indications
- Regulatory submissions and product approvals
Key Technologies
- Intracellular-signaling-targeted small-molecule discovery
- PDE1 inhibition
- Platform drug-discovery workflows
- Clinical development processes for CNS therapeutics